Value Vision Consulting is a management consulting firm focused on pharmaceuticals. It helps clients identify and secure the value of drug assets at all stages of the lifecycle. The firm's founder, Dr. Véronique Foutel, has over 20 years of experience in market access and pricing at Roche. Value Vision Consulting provides services to biopharma companies, investors, lawyers, and other stakeholders. Its unique selling points include the founder's industry experience, seniority, solution relevance, and business flexibility. The firm also relies on a network of experts to support client projects.

1. About us, our intervention scope, customers,
business solutions and unique selling points
Dr Véronique Foutel
Founder & Managing Partner
2018
Value Vision Consulting SAS,
R.C.S.Paris – SIRET 809 726 615 00010
58 rue du Faubourg Poissonnière F-75010 PARIS, FRANCE
+33.(0)1.44.56.94.50, +33 (0)6.13.42.51.65
v.foutel@valuevisionconsulting.com
www.valuevisionconsulting.com

2. About us
Dr Véronique Foutel, President of Value Vision Consulting
2
▪ Doctorate in pharmaceutical science (1984 – 1995) & Paris Hospital residency (1991 – 1995)
▪ GlaxoWelcome France (1996)
▪ F. Hoffmann La Roche AG – Pharma Division (France, Canada, Global & emerging markets) (1996 – 2012)
✓ Market access & strategic pricing for the whole Roche pipeline & portfolio (1996 – 2009)
✓ Market access & pricing applied to licensing, Due Diligence and M&A activities (2004 – 2009)
✓ Corporate exercises (such as European Commission Sector inquiry (2008-2009)….)
✓ Business compliance in direct markets (2009 – 2012)
▪ DBV Technologies (2013-2014)
▪ Value Vision Consulting (2015 – present)
Dr. Véronique Foutel – Value Vision Consulting  2018

3. About Us
Mission
A Management consultancy dedicated to pharmaceuticals
• Offering market access oriented services - at pipeline, portfolio, franchise and asset / product level
• Aimed at detecting, confirming, growing, wrapping, delivering and protecting drug value along the entire value creation chain
(from the earliest as possible R&D stage to LOE and beyond)
• Towards all Innovation Ecosystem Stakeholders (1)
• By de-risking their investment uncertainty and securing rewarding and sustainable market conditions for assets and products
• By operating on its own or with a network of business partners at the national and international levels as required by the
assignments
Dr. Véronique Foutel – Value Vision Consulting  2018 3
(1) All key stakeholders successively financing an asset along the entire value chain

4. Value Potential
identification
&
Pricing
Anchoring
Value
Development
&
Pricing
Refinement
Value
Wrapping
&
Pricing
Policy
Value
Protection
&
Pricing
Defense
POC / POD US FDA / EMA
filing
Access LOE
Asset Access Solutions
Country Negotiations /
HTA Submissions
POC Proof of Concept
POD Proof of Developability
LOE Loss of Exclusivity
HTA Health Technology Assessment
Intervention scope
Caring about value at all LC stages to secure asset access
Dr. Véronique Foutel – Value Vision Consulting  2018 4

5. Intervention scope
Towards many functional harbors
5Dr. Véronique Foutel – Value Vision Consulting  2018
R&D
(asset, pipeline, portfolio
assessment for in-house &
partnering activities)
MKTG
(access, pricing, sales
forecasting, project
management)
Legal
(sector inquiry, competition
law, MA litigations,
patenting)
Management / Corporate
(business compliance,
geography expansion,
specific MA & pricing
matters, public affairs)
BD
(Licensing-in, -out, DD)

6. Our Customers
All innovation ecosystem stakeholders
▪ The Technology Transfer Offices (TTO), the Technology Transfer Acceleration Companies (TTAC)
▪ Venture Capitalists (VC), Public investors (such as Bpi),
▪ European and Global Headquarters of Biopharma companies
▪ US and European Biotech companies,
▪ French affiliates of international Biopharma Industry, small /medium size pharma enterprises (SME) without a fully-fledged affiliate
in France, French distributors of foreign pharma companies
▪ Life science lawyers
Dr. Véronique Foutel – Value Vision Consulting 2018 6

7. Business Solutions
For the traditional Commercial Targets (i.e.Pharma and Biotech Companies)
General Access Solutions
Access Conditions and Competitive landscape
Scanning, Benchmarking, Strategic Access Road Map
Pricing Anchoring, Pricing Strategies, new Pricing
Models, Contracting Insights
Specific Access Solutions
Payers & proxy Payers’- KoL interviews / Advisory
Boards
Access Programmes
Formal Interactions at the EU and Country levels
(Early dialogues, applications, negotiations etc…)
Asset profiling, Target Product Profile definition, Value
Pillar identification, Value de-risking Plan, Payer Evidence
Set
Mix of General and Specific solutions depending on the disease, asset, lifecycle stage, client size and organisation
Dr. Véronique Foutel – Value Vision Consulting  2018 7
Early stage Late stage

8. Business Solutions
For Life Science Investors (LSI)
Dr. Véronique Foutel – Value Vision Consulting  2018 8
Pre-investment stage
Asset evaluation & de-risking plan definition
Asset profiling & strategic positioning
Biotech mapping, portfolio and / or asset analysis/
company capability assessement
Post-investment stage
Expertise at key value check points
Contribution to corporate exercises (fundraising, partnering
decision incl. commercial DD, patenting orientations,
platform development decisions…)
Building of internal capabilities or management ad interim
As strategic deal advisor As LSI business partner

9. Business solutions
Towards Life Science Lawyers
Drug Market
Access litigations
M&A / drug
licensing (in/out)
Competition law
matters
(pharmaceuticals)
Drug patenting
Biotech
commercial op.
set up
in F, EU, CH
Dr. Véronique Foutel – Value Vision Consulting  2018 9
When and where interdisciplinary approach may help shed some new light

10. Our Unique Selling Points
Dr. Véronique Foutel – Value Vision Consulting 2018
Profile
consultants being ex-
industrials knowing well
both sides
Seniority
(+ 20 years,
French, EU &
WW
practices )
Analogue and
solution relevance
(experience, know-how
transfer)
Business Flexibility
(mutualization of skills
and resources as required
by assignments)
In isolation, any of the below depicted features can likely be applied to our competitors
Our uniqueness comes from the combination of these four unique selling points
10

11. About our network
11
▪ We rely on a network of highly skilled
professionals and advisors.
Academics
Modelling/ HE
experts KoLs / Hospital
Pharmacists
Former HTA
executives
Biostatistics
/ Epidemiology
specialists
An International
Market Access
Consultancy
partner
Value Vision
Consulting
An International
medical
communication
agency
(*) This chart illustrates our regular ‘core-team’, drug safety specialists, Regulatory Affairs consultants as well as public affairs
experts are also available in our business constellation,
Dr. Véronique Foutel – Value Vision Consulting  2018